The distinction between qualitative and quantitative FBN1 mutations is important as this drug decreases TGF-β1 production, offsetting the increased circulating levels of this growth factor seen in Marfan syndrome and BAV (Nataatmadja et al., 2013). This evidence concerns the gene FBN1 and Marfan syndrome.